1 min read
Add as a preferred source on GoogleBristol Myers Squibb Shares Rise After Two Late-Stage Trials Deliver Results
The ALOFT-IPF trial of admilparant in adults with idiopathic pulmonary fibrosis met its primary endpoint.
Bristol Myers Squibb shares rose nearly 6% in premarket trading Monday, Oct. 12, after the company posted positive topline results from two Phase 3 trials.
The ALOFT-IPF trial evaluated admilparant in adults with idiopathic pulmonary fibrosis and met its primary endpoint.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.